Wells Fargo analyst Stephen Baxter raised the firm’s price target on Universal Health (UHS) to $259 from $249 and keeps an Overweight rating on the shares following quarterly results. Overall, modestly higher EBITDA estimates and rolling fully to 2027 estimates offsets a material increase in the odds of enhanced exchange subsidies expiring in the firm’s price target framework, Wells says.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UHS:
- Boeing upgraded, Charter downgraded: Wall Street’s top analyst calls
- Universal Health price target raised to $267 from $242 at Mizuho
- Universal Health upgraded to Outperform from Market Perform at Raymond James
- Universal Health price target raised to $231 from $206 at RBC Capital
- Universal Health price target raised to $302 from $280 at UBS